SEC Filing – Corcept Therapeutics, Incorporated

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BAKER G LEONARD JR

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

275 MIDDLEFIELD ROAD

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/14/2004

3. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	8,019	⁽³⁾	I	Sutter Hill Entrepreneurs Fund (AI), LP⁽⁴⁾
Series B Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	5,775	⁽³⁾	I	Sutter Hill Entrepreneurs Fund (AI), LP⁽⁴⁾
Series BB Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	1,228	⁽²⁾	I	Sutter Hill Entrepreneurs Fund (AI), LP⁽⁴⁾
Series C Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	7,400	⁽²⁾	I	Sutter Hill Entrepreneurs Fund (AI), LP⁽⁴⁾
Series A Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	20,304	⁽³⁾	I	Sutter Hill Entrepreneurs Fund (QP), LP⁽⁵⁾
Series B Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	14,619	⁽³⁾	I	Sutter Hill Entrepreneurs Fund (QP), LP⁽⁵⁾
Series BB Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	3,109	⁽²⁾	I	Sutter Hill Entrepreneurs Fund (QP), LP⁽⁵⁾
Series C Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	18,736	⁽²⁾	I	Sutter Hill Entrepreneurs Fund (QP), LP⁽⁵⁾
Series A Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	791,586	⁽³⁾	I	Sutter Hill Ventures, a California Limited Partnership⁽⁶⁾
Series B Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	569,940	⁽³⁾	I	Sutter Hill Ventures, a California Limited Partnership⁽⁶⁾
Series BB Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	121,780	⁽²⁾	I	Sutter Hill Ventures, a California Limited Partnership⁽⁶⁾
Series C Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	732,882	⁽²⁾	I	Sutter Hill Ventures, a California Limited Partnership⁽⁶⁾
Series A Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	207	⁽³⁾	D
Series BB Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	3,369	⁽²⁾	D
Series C Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	201,863	⁽²⁾	D
Series A Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	6,279	⁽³⁾	I	By trust⁽⁹⁾
Series B Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	4,521	⁽³⁾	I	By trust⁽⁹⁾
Series BB Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	966	⁽²⁾	I	By trust⁽⁹⁾
Series C Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	5,812	⁽²⁾	I	By trust⁽⁹⁾
Series A Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	110,544	⁽³⁾	I	By limited partnership⁽⁷⁾
Series B Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	77,322	⁽³⁾	I	By limited partnership⁽⁷⁾
Series BB Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	12,392	⁽²⁾	I	By limited partnership⁽⁷⁾
Series C Preferred Stock	⁽¹⁾	⁽⁸⁾	Common Stock	56,516	⁽²⁾	I	By limited partnership⁽⁷⁾

Explanation of Responses:

1. Immediately

2. Each share is convertible without consideration into one (1) share of Common Stock.

3. Each share is convertable without consideration into three (3) shares of Common Stock.

4. The reporting person is a managing director of the general partner of Sutter Hill Entrepreneurs Fund (AI), LP and shares voting and investment power with seven other managing directors of the general partner of the entity that owns the reported securites. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

5. The reporting person is a managing director of the general partner of Sutter Hill Entrepreneurs Fund (QP), LP and shares voting and investment power with seven other managing directors of the general partner of the entity that owns the reported securites. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

6. The reporting person is a managing director of the general partner of Sutter Hill Ventures, A California Limited Partnership and shares voting and investment power with six other managing directors of the general partner of the entity that owns the reported securites. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

7. The reporting person is a general partner of the limited partnership. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

8. Not applicable

9. The reporting person is a trustee of the trust. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interst therein.

	/s/ Fred Kurland, CFO of Corcept Therapeutics Incorporated attorney-in-fact	04/14/2004
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

rrd30245_35021.html

POWER OF ATTORNEY FOR SECTION 16 REPORTING
The undersigned hereby appoints Joseph K. Belanoff, in his capacity as
Chief Executive Officer of Corcept Therapeutics Incorporated (the
"Company"), Andew Galligan, in his capacity as Chief Financial Officer of the
Company, and either of them with full power of substitution or their respective
successors in any such offices, as the attorney-in-fact of the undersigned to
execute and file with the Securities and Exchange Commission ("SEC") and
any other authority required by the rules and regulations of the SEC or any
market or exchange on which shares of the Company are traded and to submit
to the Company, in the place and stead of the undersigned, SEC Forms 3, 4 and
5 and any successor reporting forms required by the SEC in connection with
purchases and sales of securities of the Company and any other transactions in
securities of the Company reportable on any such form. This Power of
Attorney shall be effective until revoked by a written instrument executed by
the undersigned and delivered to the Company at its headquarters to the
attention of the Chief Financial Officer.
Dated: February 12, 2002

/s/ G. Leonard Baker, Jr.
Name: G. Leonard Baker, Jr.